Condition: Ulcerative Colitis · Sponsor: Bausch Health Americas, Inc.
This is a randomized, double-blind, placebo-controlled, multicenter, study to evaluate the efficacy, safety, and pharmacokinetics (PK) of budesonide extended-release tablets for the induction of remission in pediatric subjects, with active, mild to moderate ulcerative colitis (UC). Subjects will be permitted to continue taking background oral or rectal 5-aminosalicylate (5-ASA) products.
This description comes directly from the study's public registry record.
Sandra Narain · 9082428287 · sandra.narain@bauschhealth.com
Always discuss trial participation with your own doctor first.
| Bausch Health Site 008 | Garden Grove, California, United States | Recruiting |
| Bausch Health Site 003 | Indianapolis, Indiana, United States | Recruiting |
| Bausch Health Site 006 | The Bronx, New York, United States | Recruiting |
| Bausch Health Site 010 | Greenville, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04314375